The global genitourinary drugs market size was USD 29.39 billion in 2023, calculated at USD 29.71 billion in 2024 and is projected to surpass around USD 33.15 billion by 2034, expanding at a CAGR of 1.1% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Genitourinary Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Genitourinary Drugs Market Revenue and Volume, by Indication, 2024-2034
8.1.1. Prostate Cancer
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Ovarian Cancer
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Bladder Cancer
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Cervical Cancer
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Renal Cancer
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. Erectile Dysfunction
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
8.1.7. Urinary Tract Infections
8.1.7.1. Market Revenue and Volume Forecast (2021-2034)
8.1.8. Urinary Incontinence & Overactive Bladder
8.1.8.1. Market Revenue and Volume Forecast (2021-2034)
8.1.9. Sexually Transmitted Diseases
8.1.9.1. Market Revenue and Volume Forecast (2021-2034)
8.1.10. Interstitial Cystitis
8.1.10.1. Market Revenue and Volume Forecast (2021-2034)
8.1.11. Haematuria
8.1.11.1. Market Revenue and Volume Forecast (2021-2034)
8.1.12. Benign Prostatic Hyperplasia
8.1.12.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Genitourinary Drugs Market Revenue and Volume, by Product, 2024-2034
9.1.1. Urologicals
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Hormonal Therapy
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Gynecological
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Anti-infectives
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Indication (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Product (2021-2034)
11.1. GlaxoSmithKline
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. CytoSorbents Corporation
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cardinal Health
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Asahi Kasei
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. ConvaTec
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. CHIESI Farmaceutici
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Smith & Nephew
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample